Sawai Group Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Sawai Group Holdings wird ein jährliches Gewinn- und Umsatzwachstum von 2.7% bzw. 7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 4.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 9.7% betragen.

Wichtige Informationen

2.7%

Wachstumsrate der Gewinne

4.2%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	11.7%
Wachstumsrate der Einnahmen	7.0%
Zukünftige Eigenkapitalrendite	9.7%
Analystenabdeckung	Good
Zuletzt aktualisiert	20 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Now The Time To Put Sawai Group Holdings (TSE:4887) On Your Watchlist?

Sep 04

Sawai Group Holdings Co., Ltd. (TSE:4887) Shares Could Be 47% Below Their Intrinsic Value Estimate

Aug 12

Sawai Group Holdings (TSE:4887) Has A Pretty Healthy Balance Sheet

Jul 27

Is Now The Time To Put Sawai Group Holdings (TSE:4887) On Your Watchlist?

May 28

Is There An Opportunity With Sawai Group Holdings Co., Ltd.'s (TSE:4887) 41% Undervaluation?

Apr 22

Is Sawai Group Holdings (TSE:4887) A Risky Investment?

Mar 06

Gewinn- und Umsatzwachstumsprognosen

TSE:4887 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	222,856	22,702	15,238	35,550	9
3/31/2026	210,380	20,695	10,603	32,491	11
3/31/2025	191,814	28,128	16,130	36,879	10
9/30/2024	177,338	16,552	-4,920	19,972	N/A
6/30/2024	168,201	17,756	-3,767	18,698	N/A
3/31/2024	176,862	17,218	-1,500	23,149	N/A
12/31/2023	185,309	17,709	-1,562	23,849	N/A
9/30/2023	191,324	14,545	-18,591	18,350	N/A
6/30/2023	205,102	12,513	-23,343	14,446	N/A
3/31/2023	200,344	12,667	-14,115	13,026	N/A
12/31/2022	196,280	-33,307	-18,371	11,249	N/A
9/30/2022	192,928	-31,031	-1,592	17,320	N/A
6/30/2022	191,561	-30,904	4,401	24,856	N/A
3/31/2022	193,816	-28,269	10,966	34,310	N/A
12/31/2021	193,149	10,835	18,198	41,875	N/A
9/30/2021	194,349	10,962	13,809	40,262	N/A
6/30/2021	193,763	13,177	9,912	34,797	N/A
3/31/2021	187,219	12,340	10,733	31,857	N/A
12/31/2020	184,968	19,348	12,664	29,573	N/A
9/30/2020	182,228	19,107	14,772	28,534	N/A
6/30/2020	179,345	18,313	13,519	31,840	N/A
3/31/2020	182,537	19,279	12,083	30,256	N/A
12/31/2019	186,610	19,891	24,260	41,627	N/A
9/30/2019	186,030	19,831	42,681	59,020	N/A
6/30/2019	186,177	20,554	33,435	43,615	N/A
3/31/2019	184,341	19,376	32,216	42,924	N/A
12/31/2018	189,526	16,777	N/A	N/A	N/A
9/30/2018	186,102	15,743	9,009	26,361	N/A
6/30/2018	179,720	14,619	N/A	N/A	N/A
3/31/2018	168,068	14,017	N/A	28,472	N/A
12/31/2017	147,592	16,268	N/A	N/A	N/A
9/30/2017	137,770	16,140	N/A	10,997	N/A
6/30/2017	133,126	16,213	N/A	N/A	N/A
3/31/2017	132,428	15,914	N/A	20,628	N/A
12/31/2016	132,490	16,840	N/A	N/A	N/A
9/30/2016	129,950	17,222	N/A	24,152	N/A
6/30/2016	127,054	16,421	N/A	N/A	N/A
3/31/2016	123,492	17,155	N/A	19,975	N/A
12/31/2015	117,641	16,353	N/A	N/A	N/A
9/30/2015	114,210	15,554	N/A	14,914	N/A
6/30/2015	109,716	15,706	N/A	N/A	N/A
3/31/2015	105,454	14,053	N/A	12,112	N/A
12/31/2014	102,083	13,064	N/A	N/A	N/A
9/30/2014	97,279	12,713	N/A	8,730	N/A
6/30/2014	93,041	11,860	N/A	N/A	N/A
3/31/2014	89,823	12,192	N/A	13,422	N/A
12/31/2013	87,423	13,017	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 4887Das prognostizierte Gewinnwachstum (2.7% pro Jahr) liegt über der Sparquote (0.3%).

Ertrag vs. Markt: 4887Die Erträge des Unternehmens (2.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt JP (7.9% pro Jahr).

Hohe Wachstumserträge: 4887Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 4887Die Einnahmen des Unternehmens (7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt JP (4.1% pro Jahr).

Hohe Wachstumseinnahmen: 4887Die Einnahmen des Unternehmens (7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 4887Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (9.7%).

Sawai Group Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates increase by 24%

Consensus EPS estimates increase by 11%, revenue downgraded

Consensus EPS estimates increase by 40%, revenue downgraded

Price target increased by 12% to JP¥5,863

Price target increased by 7.3% to JP¥5,586

Consensus EPS estimates fall by 12%

Recent updates

Upcoming dividend of JP¥78.00 per share

Is Now The Time To Put Sawai Group Holdings (TSE:4887) On Your Watchlist?

Sawai Group Holdings Co., Ltd. to Report Q2, 2025 Results on Nov 11, 2024

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Sawai Group Holdings Co., Ltd. (TSE:4887) Shares Could Be 47% Below Their Intrinsic Value Estimate

Sawai Group Holdings (TSE:4887) Has A Pretty Healthy Balance Sheet

Final dividend of JP¥78.00 announced

Sawai Group Holdings Co., Ltd. (TSE:4887) announces an Equity Buyback for 6,900,000 shares, representing 15.75% for ¥33,000 million.

Sawai Group Holdings Co., Ltd. to Report Q1, 2025 Results on Aug 09, 2024

Is Now The Time To Put Sawai Group Holdings (TSE:4887) On Your Watchlist?

Consensus EPS estimates increase by 24%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2024

Is There An Opportunity With Sawai Group Holdings Co., Ltd.'s (TSE:4887) 41% Undervaluation?

Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887).

Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887).

Now 21% undervalued

Upcoming dividend of JP¥65.00 per share

Is Sawai Group Holdings (TSE:4887) A Risky Investment?

Consensus EPS estimates increase by 11%, revenue downgraded

Sawai Group Holdings Co., Ltd. to Report Q4, 2024 Results on May 13, 2024

Consensus EPS estimates increase by 40%, revenue downgraded

Now 21% undervalued

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 12% to JP¥5,863

Price target increased by 7.3% to JP¥5,586

Consensus EPS estimates fall by 12%

Sawai Group Holdings Co., Ltd. to Report Q3, 2024 Results on Feb 14, 2024

Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Upcoming dividend of JP¥65.00 per share at 2.8% yield

Price target increased by 9.9% to JP¥4,734

Sawai Group Holdings Co., Ltd. to Report Q2, 2024 Results on Nov 10, 2023

Price target increased by 7.5% to JP¥4,308

First quarter 2024 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 10%

Consensus EPS estimates increase by 14%

Sawai Group Holdings Co., Ltd. to Report Q1, 2024 Results on Aug 09, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half Year Ending September 2023 and Fiscal Year Ending March 31, 2024

Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 27, 2023

Price target decreased by 9.2% to JP¥4,169

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Sawai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Sawai Group Holdings Co., Ltd. to Report Q3, 2023 Results on Feb 13, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Sawai Group Holdings Co., Ltd. Announces Dividend for the Second Quarter Ending September 30, 2022, Payable on December 2, 2022; Provides Dividend Guidance for the Year Ending March 31, 2023

Upcoming dividend of JP¥65.00 per share

Sawai Group Holdings Co., Ltd. to Report Q2, 2023 Results on Nov 08, 2022

Price target increased to JP¥4,630

Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2023

Price target decreased to JP¥4,561

Sawai Group Holdings Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd. Announce Notice of Filing an Appeal in Patent Infringement Lawsuit Concerning Edirol Capsule

Sawai Group Holdings Co., Ltd. to Report Q1, 2023 Results on Aug 12, 2022

Sawai Group Holdings Co., Ltd. Provides Earnings Guidance for Period Ending September 2022 and Year Ending March 2023

Consensus EPS estimates fall by 83%

Less than half of directors are independent

Upcoming dividend of JP¥65.00 per share

Sawai Group Holdings Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022

Sawai Pharmaceutical Co., Ltd. Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2022

Second quarter 2022 earnings released: EPS JP¥71.13 (vs JP¥122 in 2Q 2021)

Upcoming dividend of JP¥65.00 per share

Full year 2021 earnings released: EPS JP¥282 (vs JP¥440 in FY 2020)

Full year 2021 earnings released: EPS JP¥282 (vs JP¥440 in FY 2020)

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie